SCNX

COMMACK, NY / ACCESS Newswire / June 4, 2026 / SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that members of its executive management team will participate in The Small Cap Showcase & WTR Insights, taking place on June 9, 2026, in New York City.Narasimhan Mani, President, co-CEO and Interim CFO of Scienture, will deliver a corporate presentation at 1:30 p.m. ET. A live webcast of the Company's presentation will

U.S. Naloxone Market: ~$141 million in annual sales and 9.4 million units annually COMMACK, NY, June 02, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that the United States Patent and Trademark Office has granted U.S. Patent No. 12,622,903 B2, patent covering REZENOPY™ (naloxone HCl) Nasal Spray 10 mg, effective May 12, 2026, with an expiry date of February 5, 2041. The patent was i

8-K - Scienture Holdings, Inc. (0001382574) (Filer)

8-K - Scienture Holdings, Inc. (0001382574) (Filer)

COMMACK, NY, May 18, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) ("Scienture"), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today provided a business update and reported financial results for the three months ended March 31, 2026. Q1 2026 Financial Highlights Compared to Q1 2025: Revenue increased to approximately $56 thousand for the three months ended March 31, 2026, compared to approximately $10 thousand in the prior-year three-month peri

10-Q - Scienture Holdings, Inc. (0001382574) (Filer)

Proceeds support commercialization of Arbli™, the first FDA-approved ready-to-use oral suspension for hypertension; and REZENOPY™, life-saving opioid overdose emergency treatment Financing also drives early- and late-stage clinical execution of diverse pipeline spanning multiple therapeutic areas COMMACK, NY, May 07, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) ("Scienture") a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced it has secured $

U.S. losartan market totals approximately $241M annually with around 72M prescriptions, creating a significant opportunity for ARBLI™ as the first FDA-approved ready-to-use oral suspension COMMACK, NY, May 06, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that the United States Patent and Trademark Office (USPTO) has granted its third patent covering ARBLI™ (losartan potassium) oral s

8-K - Scienture Holdings, Inc. (0001382574) (Filer)

8-K - Scienture Holdings, Inc. (0001382574) (Filer)

10-K/A - Scienture Holdings, Inc. (0001382574) (Filer)

COMMACK, NY, April 15, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) ("Scienture") a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced that on April 14, 2026, it received notification from The Nasdaq Stock Market LLC ("Nasdaq") that Nasdaq approved the Company's request for an additional 180-calendar day extension to regain compliance with the minimum closing bid price requirement of $1.00 per share. The Company now has until October 12, 2026 to

COMMACK, NY, April 06, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) ("Scienture") a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today provided an annual update from its Co-Chief Executive Officers, Narasimhan Mani and Shankar Hariharan, to its shareholders: To Our Valued Shareholders, This past year marked a pivotal period for Scienture, as we advanced our strategy to build a differentiated, branded specialty pharmaceutical platform. We are pleased to s

Reports Significant Revenue Growth and Gross Margin Expansion in 2025 COMMACK, NY, March 30, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) ("Scienture"), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today provided a business update and reported financial results for the year ended December 31, 2025. 2025 Financial Highlights Compared to 2024: Net revenue increased 216% to $431,609 from $136,643Gross Margin Expanded by 7,240 Basis Points to 76.

10-K - Scienture Holdings, Inc. (0001382574) (Filer)

4 - Scienture Holdings, Inc. (0001382574) (Issuer)

4 - Scienture Holdings, Inc. (0001382574) (Issuer)

Expands institutional footprint with potential penetration of more than ~ 60% of the U.S. market, while expanding reach across EMS providers and rehabilitation centers U.S. naloxone market totals $141M with 9.4 million prescription units annually, represents significant commercial opportunity for REZENOPY™ COMMACK, NY, March 11, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that it h

Company highlights accelerating access and revenue growth for ARBLI™ and confirms REZENOPY™ launch timeline, addressing a combined US annual losartan and naloxone market size of close to $385 million Outlines Q1 2026 outlook and reports significant balance sheet improvement last quarter COMMACK, NY, Feb. 03, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today provided a commercial update on ARBLI™ (

U.S. Naloxone Market: ~$154 million in annual sales and 9.3 million units annually COMMACK, NY, Jan. 14, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,514,854 B2, an Orange Book-listable patent covering REZENOPY™ (naloxone HCl) Nasal Spray 10 mg, effective January 6, 2026, with an expiry date of February

U.S. Naloxone Market: ~$154 million in annual sales and 9.3 million units annually COMMACK, NY, Dec. 22, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today provided an update on the commercial launch of REZENOPY®. As previously disclosed, Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc. entered into a definitive agreement with Summit Biosciences Inc. (a Kindeva subsidiary) in M

U.S. Losartan market totals $245M annually with 71M prescriptions  COMMACK, NY, Dec. 10, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, and Blink Rx LLC ("BlinkRx"), one of the most advanced patient access platforms for branded medications, today announced a strategic collaboration to expand national access to Arbli™, the first FDA-approved, ready-to-use oral suspension formulation of losartan potassi

COMMACK, NY, Dec. 02, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that management will be participating in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th - 10th, 2025. Narasimhan Mani, President and co-CEO of Scienture is scheduled to present at 2:00 PM EST on December 9th. Shankar Hariharan, Executive Chairman and co-CEO of Scienture, will jo

8-K - Scienture Holdings, Inc. (0001382574) (Filer)

8-K - Scienture Holdings, Inc. (0001382574) (Filer)